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HIV-1 protease inhibitors (PIs) have antimalarial activity in vitro and in murine models. The potential beneficial effect of HIV-1
PIs onmalaria has not been studied in clinical settings. We used data from Adult AIDS Clinical Trials Group A5208 sites where
malaria is endemic to compare the incidence of clinically diagnosed malaria among HIV-infected adult women randomized to
either lopinavir/ritonavir (LPV/r)-based antiretroviral therapy (ART) or to nevirapine (NVP)-based ART.We calculated hazard
ratios and 95% confidence intervals. We conducted a recurrent events analysis that included both first and second clinical malar-
ial episodes and also conducted analyses to assess the sensitivity of results to outcomemisclassification. Among the 445 women
in this analysis, 137 (31%) received a clinical diagnosis of malaria at least once during follow-up. Of these 137, 72 (53%) were
randomized to LPV/r-based ART. Assignment to the LPV/r treatment group (n 226) was not consistent with a large decrease in
the hazard of first clinical malarial episode (hazard ratio 1.11 [0.79 to 1.56]). The results were similar in the recurrent events
analysis. Sensitivity analyses indicated the results were robust to reasonable levels of outcomemisclassification. In this study, the
treatment with LPV/r compared to NVP had no apparent beneficial effect on the incidence of clinical malaria among HIV-
infected adult women. Additional research concerning the effects of PI-based therapy on the incidence of malaria diagnosed by
more specific criteria and among groups at a higher risk for severe disease is warranted.
HIV and malaria are highly coprevalent infections in severalregions of the world, including sub-Saharan Africa. An anti-
retroviral treatment for HIV that is also effective in treating or
preventing malaria would have important clinical implications to
the millions of HIV-infected individuals residing in areas where
malaria is endemic.
The effects of HIV infection on malaria and of malaria infec-
tion on HIV have been well documented, although the precise
interactions between these two pathogens are incompletely un-
derstood.HIV infection increases the incidence ofmalaria (10, 27,
35); malaria increases HIV viral replication (18, 20) and decreases
CD4 counts in individuals infected with HIV (22). Although drug
interactions between antiretroviral therapies (ART) and antima-
larials are only partially understood, there are examples of harm-
ful effects for the coinfected patient (11) and alterations in the
pharmacokinetics of several drugs that are used to treat HIV and
malaria (12, 19, 32). An antiretroviral treatment regimen that not
only inhibits HIV replication and improves immunologic compe-
tency but also has inhibitory activity against the Plasmodium par-
asite is highly desirable. There is emerging evidence that HIV pro-
tease inhibitors (PIs) may fill that role (3, 17, 26, 29, 28, 33).
In vitro studies have demonstrated that HIV PIs inhibit the
growth of Plasmodium falciparum in both drug-sensitive and
drug-resistant parasites (3, 33, 26). Parasites exposed to sera taken
fromHIV-infected subjects being treated with a coformulation of
lopinavir and ritonavir (LPV/r) underwent a 59 to 95% reduction
in growth compared to parasites exposed to sera from control
subjects (29). In vivo evidence frommurine models also supports
the antimalarial effect of HIV PIs (3, 17). Nathoo et al. proposed
that HIV PIs may have an impact on individuals withmalaria that
is independent of its antiparasitic effects after in vitro observations
demonstrated that treating cells withHIVPIs resulted in amarked
reduction in the expression of CD36, a human cell receptor asso-
ciated with the sequestration of the malaria parasite, compared to
control cells not treated with a PI (24).
PI-basedART is not currently a recommendedfirst-line option
in resource-limited settings (38). However, the recent develop-
ment of a heat-stable LPV/r tablet, coupled with the broader
degree of resistance found in patients failing first-line non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based ART
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(14) and the risk of NNRTI resistance in HIV-infected pregnant
women who received single-dose NVP (sdNVP) for the preven-
tion of mother-to-child transmission (PMTCT) (4), makes it
likely that the use of PIs in the developing world will increase. If a
direct antimalarial effect of HIV PIs is found to be clinically rele-
vant in humans, their use in highly prevalent HIV regions where
malaria is also prevalentwould be evenmore valuable, particularly
for patients coinfected with HIV and P. falciparum malaria, de-
spite the increased expense relative to NVP.
The AIDS Clinical Trials Group (ACTG) recently completed
two phase III randomized clinical trials (A5208) comparing the
antiretroviral activity of LPV/r-based ART to NVP-based ART in
ART-naive, HIV-infected women who had been exposed to
sdNVP (trial 1) or who had no history of NVP use (trial 2). We
conducted a secondary analysis using data derived from A5208 to
measure the association between LPV/r and clinical malaria as
defined by a compatible clinical syndrome.
MATERIALS AND METHODS
ACTGA5208.The study consisted of two open label trials thatmonitored
subjects for at least 48 weeks after the final participant was randomized
(21). Trial 1 enrolled HIV-infected women who had received sdNVP for
PMTCT (n 243); trial 2 enrolled HIV-infected women with no history
of NVP exposure (n 502) (21). In both trials, the subjects were stratified
by screening CD4 cell count (50 cells/l and 50 cells/l) and ran-
domized in a 1:1 ratio to receive either LPV/r-based ART or NVP-based
ART. All subjects also received tenofovir disoproxil fumarate and emtric-
itabine (in addition to LPV/r or NVP), which is consistent with World
Health Organization) guidelines (38). Subjects had regularly scheduled
study visits (at weeks 2, 4, 8, 12, 16, and 24 and then every 12 weeks),
during which the patient’s health was assessed, and any clinical diagnoses
were recorded. Subjects could also report to the study site formedical care
as needed.
Study population. A5208 enrolled women older than 13 years of age
(or older as dictated by the study site’s Institutional Review Board [IRB])
with a CD4 cell count of200 cells/mm3 obtained within 90 days prior
to study entry. The study was conducted at 10 ACTG-sponsored sites in
sub-Saharan Africa: one each in Botswana,Malawi, Uganda, Zambia, and
Zimbabwe, two in Kenya, and three in South Africa. Enrollment criteria
are described in detail elsewhere (21). We used data from subjects in both
trials from the five countries where malaria transmission is known to
occur: Kenya (two sites), Malawi, Uganda, Zambia, and Zimbabwe. We
excluded one participant (randomized to NVP in trial 2) who had prob-
able clinical malaria at baseline, according to the definition below.
Exposure and outcome. The main exposure was the therapeutic reg-
imen to which the participant was randomized (i.e., LPV/r-based ART or
NVP-based ART). The primary outcome was the incidence of clinical
malaria and included both confirmed and probable diagnoses. Confirmed
malaria in study subjects was defined in ACTG appendix 60 as both a
“compatible clinical syndrome” and the identification of Plasmodium sp.
on a peripheral blood smear (2). Probable malaria was defined as a “com-
patible clinical syndrome” in subjects who received or who were recom-
mended to receive antimalarial treatment (this group included subjects in
which no peripheral blood smear was obtained and in those with a nega-
tive peripheral blood smear) (2). “Compatible clinical syndrome” was
determined by on-site clinicians, typically either a physician or clinical
officer, and was based on clinical judgment alone with no standardized
documentation required.
Statistical analysis. All analyses were intent to treat. In our primary
analysis, we only considered the first episode of malaria. We counted
time-on-treatment from randomization until the date of malaria diagno-
sis (either confirmed or probable), death, study drop-out, or study com-
pletion.Weused the hazard ratio (HR) as ameasure of association and the
95% confidence interval (CI) as a measure of precision. To estimate the
HR, we fit pooled logistic regression models, which approximate Cox
proportional hazards models as long as the event proportion in all time
periods is less than 10% (7). In our study, the largest event proportionwas
6%. Pooled logistic regression is appropriate when the data are collected
in intervals, similar to the scheduled study visits in A5208 (7). Time-on-
treatmentwasmodeled using a 5-knot restricted cubic spline (15) to allow
a flexible nonlinear association between time and clinical malaria. All
models included indicators for the specific combination of three design
variables: trial, study site, and screening CD4 cell count stratum (50
cells/l or50 cells/l). Because few subjects had165 weeks of follow-
up, we administratively censored subjects still at risk at 165 weeks.
Because the risk of malaria can have marked seasonality and concom-
itant medications given to HIV-positive individuals may possess antima-
larial activity, seasonality and concomitantmedications were examined as
possible modifiers of the HR by including them in themodels in conjunc-
tion with their product terms with treatment. Using climate data from the
National Oceanic and Atmospheric Administration (http://www7.ncdc
.noaa.gov/CDO/cdo) and evidence from the literature (1, 8, 25, 34), we
created a time-varying dichotomous variable denoting the rainy season
(indicating a higher risk of malaria transmission). We also created a
time-varying dichotomous variable that indicated current use of any
of these concomitant medications known to possess antimalarial
activity: azithromycin, clindamycin, diaminodiphenylsulfone (dapsone),
doxycycline hydrochloride, doxycycline monohydrate, and trimethoprim-
sulfamethoxazole. We examined the proportional hazards assumption by
visually inspecting a plot of the log cumulative hazard by time and by
testing the null hypothesis which included all individual product terms for
each time variable and treatment. This did not improve model fit, as
measured by the log likelihood (alphawas set at 0.1).We also explored the
effects of LPV/r versus NVP in trial 1 and trial 2 separately. Finally, we
generated crude plots of clinical malaria-free survival by time for each
exposure group.
We conducted two sensitivity analyses to address possible bias from
outcome misclassification. First, we fit a model in which only confirmed
malaria cases were considered to have experienced a malaria episode (a
person with a diagnosis of probable malaria was not censored at the time
of diagnosis). Second, we explored the consequences of the imperfect
specificity of clinically diagnosed malaria on the effects of treatment as-
signment by calculating risk ratios (RR), first from the observed data and
again after correcting the observed numbers of cases, using a sensitivity
analysis method described by Greenland (13).
We conducted a separate analysis to assess the treatment effect on all
episodes of clinical malaria within the study period (as described above,
combining confirmed and probable). In the analysis of recurrent malaria
infections, subjects had to have at least one visit with no clinical malaria
diagnosis (neither confirmed nor probable) between episodes. This was
done in an effort to reduce potential misclassification of recurrent epi-
sodes as treatment failures as opposed to the acquisition of a newmalarial
infection.
We again used pooled the logistic regression to estimate HR and 95%
CI values. We used a person-spell-week data structure (5, 36). Subjects
remained in the first spell until they experienced clinical malaria, death,
drop-out, or study completion. If a subject experienced clinical malaria,
she remained in the first spell until death, drop-out, study completion, or
a visit in which no clinicalmalaria was present. If the latter, the participant
moved immediately into the second spell, indicating that the participant
was again at risk for clinical malaria; this process was repeated until com-
pletion of follow-up. We used generalized estimating equations with an
exchangeable covariance matrix to efficiently estimate robust standard
errors that account for within-participant correlation.Wemodeled time-
within-spell by using a 5-knot restricted cubic spline (15). We included
trial, study site, and screening CD4 cell count in this model; we also in-
cluded indicator variables to adjust for spell. As in the primary analysis, we
examined seasonality and concomitantmedication as possible effectmea-
sure modifiers; we also assessed interaction between treatment and spell.
Porter et al.
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The nonrandommovement fromone spell to the next in this analysis (i.e.,
the data cannot be considered randomized after the first spell) may have
introduced bias, the direction and magnitude of which is difficult to pre-
dict, and therefore the results need to be interpreted cautiously.
A5208 was approved by all appropriate local and U.S. IRBs and ethics
committees, and all participants provided written informed consent. This
secondary analysis included only de-identified data and was determined
to be exempt from IRB review. All analyses were conducted using SAS
statistical software (version 9.2; SAS Institute, Cary, NC).
RESULTS
There were 145 women from trial 1 included in this analysis. A
total of 72 were assigned LPV/r and 73 were assigned NVP. The
baseline demographics, including mean age, CD4 lymphocyte
count, and plasma HIV-1 RNA levels, were comparable between
the arms (Table 1). The subjects in trial 1weremonitored for up to
184 weeks; eight were administratively censored at 165 weeks. The
mean duration of follow-up was 89 weeks. In trial 1, 53 subjects
(37%) received a clinical diagnosis of confirmed or probable ma-
laria at least once during follow-up (Table 2). Of these 53, 12
subjects (23%) had confirmedmalaria as their first episode (Table
2), and 18 subjects (34%) had one or more additional episodes of
confirmed or probable malaria.
There were 300 women from trial 2 included in this analysis. A
total of 154 were assigned LPV/r, and 146 were assigned NVP
(Table 1). The mean ages and median viral loads were similar
across treatment arms within trial 2 (Table 1). The subjects in trial
2 were followed for up to 192 weeks; 27 were administratively
censored at 165 weeks. The mean duration of follow-up was 93
weeks. In trial 2, 84 subjects (28%) received a confirmed or prob-
able diagnosis of malaria at least once during follow-up (Table 2).
Eighteen of these 84 (21%) had confirmed malaria. Of the 84
subjects with a confirmed or probable diagnosis of malaria, 37
(44%) had more than one episode.
Based on the plot of the log cumulative hazard as well as the P
value for the testing of the benefit of the addition of product terms
of treatment assignment and time (P  0.63), we concluded the
proportional hazards assumption was acceptably met. Assign-
ment to LPV/r-based therapy (n 226) was not consistent with a
decrease in the hazard of clinical malaria (HR for LPV/r versus
NVP  1.11 [95% CI  0.79 to 1.56]) (Table 3). Kaplan-Meier
curves are presented in Fig. 1. The HRs estimated for the analyses
stratified by trial were similar (Table 3). Trial-specific curves are
presented in Fig. 2. Strong modification of the HR by seasonality
or use of concomitant medications was not apparent (the P value
for the product term of treatment and seasonality was 0.83; the P
value for the product term of treatment and concomitant medi-
cations was 0.65).
When we considered only confirmed cases of malaria, the
results were not substantially different. Although there was an
increase in the hazard of malaria among the LPV/r treatment
group, this estimate was imprecise and compatible with no
association (HR for LPV/r versus NVP 1.34 [95% CI 0.64
to 2.79]) (Table 3).
When we corrected the observed number of cases for specific-
ity of the outcome to 100%, we found that, at reasonably high
specificities, the lack of an observed protective effect of LPV/r was
robust (at 90% specificity, the RR  1.03; at 80% specificity, the
RR 1.05).However, at specificities of 70%or less, the number of
“true” cases was quite small (1), making the estimate of the
effect unstable.
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A total of 137 subjects experienced at least one episode of clin-
ical malaria, and 55 experienced a second episode of clinical ma-
laria while on the study. Since only 14 subjects experienced three
or more episodes of clinical malaria, we limited the recurrent
events analysis to the first two episodes. These results were also
compatible with no reduction in the hazard of clinicalmalaria and
assignment to LPV/r between treatment assignment and the haz-
ard of clinical malaria (Table 3). There did not appear to be a
meaningful interaction between treatment and spell (P  0.43).
Strong modification of the HR by seasonality or use of concomi-
tant medications was also not apparent in this model (the P value
for the product term of treatment and seasonality was 0.64, and
the P value for the product term of treatment and concomitant
medications was 0.76).
DISCUSSION
The results reported here are consistent with no or little protective
effect from LPV/r versus NVP-based ART regimen on the inci-
dence of clinical malaria. Subjects randomized to LPV/r-based
ART were as, or more, likely to develop clinically diagnosed ma-
laria as subjects randomized to receive a NVP-based ART regi-
men. The results were similar across both trials of ACTG A5208
and when the analysis was restricted to only confirmed cases of
malaria.
These results are inconsistent with laboratory evidence sup-
porting an antimalarial effect of HIV PIs. Skinner-Adams et al.
demonstrated the inhibitory effects of ritonavir, saquinavir, and
indinavir on the in vitro growth of P. falciparum, whereas the
NNRTI NVP had no such inhibitory effect (33). Additional stud-
ies using murine models of malaria have also demonstrated the
antimalarial effect of certain HIV PIs. After infection with P. cha-
baudi, for example, mice exposed to LPV/r had a delayed onset of
parasitemia by 2 days and a decrease from 20 to 4% in median
parasitemia (3). Evidence from a different murine model infected
with P. yoelii has suggested that HIV PIs, including lopinavir
(LPV), can also inhibit the growth of pre-erythrocytic-stage par-
asites at concentrations effective to inhibit HIV-1 replication (17).
The absence of a protective effect of LPV/r on the incidence of
clinicalmalaria seen in the present study needs to be considered in
the context of the study design of the trials. Women who experi-
enced virologic failure in either trial, as well as those with adverse
reactions to their assigned medications, were eligible to switch
their antiretroviral regimen and receive the treatment available in
the other study arm. Among the 445 women included in this sec-
ondary analysis, 50 (11%) did so; almost all of these subjects
switched from a NVP-based to a LPV/r-based ART regimen. Al-
though this could have potentially influenced the results of the
study, the small percentage of subjects who actually did switch
treatment may have limited the effect that switching could have
had on our results.
There are several potential explanations for why LPV/r-based
therapy was not associated with a decrease in the incidence of
clinical malaria in the present study. First, Nathoo et al. (24) have
proposed that the decrease in CD36 expression associated with
exposure to HIV PIs, while perhaps being beneficial to the patient
in controlling P. falciparum infection, may also make it more dif-
ficult for a patient’s innate immune system to produce an effective
immune response against P. falciparum infection through its in-
hibitory effect on the nonopsonic phagocytosis of parasitized red
cells by macrophages. As a result, this reduction in the innate
immune response to malaria may have offset any potential anti-
parasitic activity of LPV/r, resulting in little or no net protective
benefit.
FIG 1 Malaria-free survival in ACTG A5208 subjects, by treatment assign-
ment. NVP, n 219; LPV/r, n 226.
TABLE 2 First episodes of clinically diagnosed malaria among subjects
of ACTG A5208
Subject category
No. of subjects
Trial 1 (n 145) Trial 2 (n 300)
LPV/r
(n 72)
NVP
(n 73)
LPV/r
(n 154)
NVP
(n 146)
All malariaa
Eldoret, Kenya 5 5 5 8
Kericho, Kenya 11 6 12 8
Lilongwe, Malawi 6 6 7 8
Kampala, Uganda 3 1 6 8
Lusaka, Zambia 4 6 12 8
Harare,
Zimbabwe
0 0 1 1
Total 29 24 43 41
Confirmed malariab 7 5 10 8
a All malaria, defined as a compatible clinical syndrome and prescription of
antimalarials.
b Confirmed malaria, defined as a compatible clinicalsyndrome and a positive blood
smear.
TABLE 3 Summary of treatment assignment and hazard of clinical
malaria in ACTG A5208
Primary analysisa Hazard ratiob (95% CI)
Overall 1.11 (0.79–1.56)
Stratified
Trial 1 1.28 (0.74–2.22)
Trial 2 1.02 (0.66–1.57)
Confirmed malaria only 1.34 (0.64–2.79)
Recurrent events analysis 1.20 (0.90–1.59)
a Survival analysis in which subjects were censored upon first episode of malaria.
b For lopinavir boosted with ritonavir-based ART compared to nevirapine-based ART.
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In addition, the concentration of LPV in the patients’ sera
might not have achieved a level sufficient enough to exert an an-
timalarial activity. In vitro activities of the HIV PIs against P. fal-
ciparum are modest compared to standard antimalarial medica-
tions, including chloroquine (3); they are also much less active
against malaria in vitro than HIV (26, 30). In addition, LPV is
highly protein bound, and free drug concentrations in plasma are
likely to be 100-fold less than measured total concentrations (9).
Although the antimalarial activity of sera taken from patients
treated with HIV PIs has been evaluated ex vivo to explore the
effect of clinically relevant peak serum concentrations (29), it is
unknown whether the parasites’ drug exposures in these labora-
tory studies are truly equivalent to the drug concentrations one
would anticipate in a patient on ART and, because there was no
systematic sampling of LPV levels in subjects who initiated LPV/r
therapy, we could not evaluate that in the present study.
Limitations to the present study include the imperfect sensitiv-
ity and specificity of relying on a clinical syndrome (6) and mi-
croscopy (37) for the diagnoses of malaria. This reduced our abil-
ity to determine the true incidence ofmalaria; however, the results
from the sensitivity analyses indicate that the results were robust
to moderate levels of outcome misclassification. Also, since the
study sites are generally in areas of high malaria transmission and
high preexisting immunity, theymay not be generalizable to areas
with low malaria transmission.
These results should be considered cautiously given the reli-
ance on clinically diagnosed malaria as the primary outcome in
the present study. Studies on the effects of PI’s on laboratory-
confirmed malaria in this study population are ongoing and will
provide additional data. In addition to studies in adults that are
designed to directly address whether PIs have a beneficial effect on
malaria in regions wheremalaria is endemic and the prevalence of
HIV-1 is high, further research is warranted to determine the ef-
fects of HIV PIs on malaria in children and pregnant women, two
groups that are at greater risk for clinical malaria. In addition,
since laboratory evidence suggests that the coadministration of
HIV PIs with additional antimalarial agents, including chloro-
quine or mefloquine, may enhance the antimalarial activity of
these drugs (16, 23, 31), the utility of such combinations also
warrants further research. In conclusion, the results from our
analyses, which were not consistent with large a decreased hazard
of clinicalmalaria in subjects receiving LPV/r-based ART, provide
evidence, albeit preliminary and imperfect, that supports the pos-
sibility of no or little effect of LPV/r-based therapy on clinical
malaria.
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